Recruiting

Nicotinamide Riboside

Sponsor:

State University of New York at Buffalo

Code:

NCT05500170

Conditions

Cognitive Impairment

Sleep Quality

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Accepted

Interventions

Nicotinamide riboside

Placebo

Study Details

Brief summary:

Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.

Conditions

Cognitive Impairment

Sleep Quality

Study ID

NCT05500170

Start date

Apr 4, 2023

Status verified date

Aug, 2025

Completion date

Aug 30, 2027

Anticipated

Primary completion date

Aug 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Sleep Quality. Pittsburgh Sleep Quality Index (PSQI) global score >5

Exclusion Criteria:

  • Dementia. Veteran Affairs - St. Louis University Mental Status questionnaire (VA-SLUMS) score <20

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Intervention

Participants in the intervention group will receive 500mg of NR twice daily

placebo comparator: Placebo

Participants in the intervention group will receive 500mg of sham placebo twice daily

Interventions

Nicotinamide riboside

Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.

Placebo

The placebo pill will contain micro cellulose powder.

Primary outcome measure

  • Sleep Quality Assessment [ Time Frame: Change from baseline to endpoint at 12 weeks ]

Central Contacts and Locations

Central contacts

Carleara Weiss, PhD, MS, RN

7168282006carleara@buffalo.edu

Rebecca A Lorenz, PhD, RN

716-829-2204rlorenz@buffalo.edu

Locations

Buffalo Veteran Affairs Medical Center

Recruiting

Buffalo, New York, United States, 14215

More Information

Sponsor

State University of New York at Buffalo

Last update posted

Aug 22, 2025

Last verified

Aug, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by State University of New York at Buffalo on 2025-08-22.